Instrument Inactif

Autres langues US Rare Earth Minerals Inc Other OTC

Actions

US9034101082

Recherche biotechnologique et médicale

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

16/07	L'italien Angelini Pharma finalise le rachat de Catalyst pour 4,1 milliards de dollars avec le soutien de l'État	RE
15/05	Bioxytran, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

16/07	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
29/05	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
15/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt
20/03	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
18/03	Bioxytran, Inc. announced that it has received $1.158942 million in funding
04/03	Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
04/03	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M
02/03	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19
23/02	Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement
11/02	Bioxytran reports positive phase 2 results demonstrating rapid viral clearance with Prolectin-Mbioxytran
11/02	Bioxytran, Inc. Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with Prolectin-Mbioxytran
11/02	Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
02/02	Bioxytran, Inc. and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
02/02	Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
29/01	Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
15/12	Bioxytran, Inc. Announces Resignation of Anders Utter from Board of Directors and Chair of Audit Committee
14/11	Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14/11	Bioxytran, Inc. announced that it has received $0.43 million in funding
13/11	Bioxytran Announces Initiation of Coverage of its Stock by Independent Research
05/11	Bioxytran, Inc. announced that it expects to receive $0.43 million in funding
29/10/25	Bioxytran Completes Randomized Clinical Trial for Its Broad-Spectrum Antiviral Drug